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A B S T R A C T
Objectives
This is a protocol for a Cochrane Review (intervention). The objectives are as follows:
To systematically review the available evidence on the eIects (benefits and harms) of DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2
inhibitors in people with established CVD, using network meta-analysis.
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B A C K G R O U N D
Description of the condition
Cardiovascular disease (CVD) is one of the most common causes
of death, leading to an estimated 17.3 million deaths annually
worldwide (Roth 2015a). As the world's population increases and
ages, so does the prevalence of CVD (Roth 2015b). The prevalence
of heart failure (HF) in the USA alone has been projected to rise
steadily over the next four decades, with an estimated 772,000
new cases projected by 2040 (Owan 2005; Ponikowski 2014), and a
similar trend has also been shown for Asian and European countries
(Maggioni 2015; Sato 2015; Conrad 2018).
To eIectively tackle this global issue, a wide array of CVD risk factors
should be considered, and of these, hypertension, dyslipidaemia
and diabetes mellitus are probably the most widely-discussed
management goals because of their corresponding prevalence
and mortality rates (Joseph 2017; Mensah 2017). Theoretically,
eIective blood glycaemic control in people with diabetes mellitus
is beneficial to reduce the incidence of CVD (IDF 2019); however,
findings from several large-scale clinical trials indicated that an
improved glycaemic control profile in diabetics only reduces the
risk of micro-vascular complications such as retinopathy, but not
the risk of macro-vascular complications such as cardiovascular
events and overall mortality (Selvin 2004). In light of the current
challenges, three new classes of glucose-lowering interventions,
namely dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like
peptide 1 (GLP-1) receptor agonists and sodium-glucose co-
transporter-2 (SGLT-2) inhibitors, have been proposed as potential
new pharmacological agents for modifying cardiovascular risks in
people with or without diabetes mellitus (Zinman 2015; Marso
2016a; McMurray 2019).
Description of the intervention
Glucose-lowering interventions were developed in the early 1900s
and remain as standard treatment options for people with diabetes
mellitus for the management of hyperglycaemia (White 2014). The
rationale behind the use of oral pharmacological agents is that
while most people with type 1 diabetes mellitus could be treated
with subcutaneous or bolus insulin infusion, for people with type
2 diabetes mellitus there could be additional treatment options
available for oral administration (ADA 2018; ADA 2019). Metformin is
the preferred initial oral glucose-lowering agent for the treatment
of type 2 diabetes mellitus (ADA 2019). The major mechanism
of action illustrated by metformin is the ability to decrease
hepatic glucose output by inhibiting gluconeogenesis (Rena 2017).
Metformin also improves insulin sensitivity and increases insulin-
mediated glucose utilisation in muscle and liver (Mclntyre 1991).
Although metformin could improve vascular function and decrease
myocardial ischaemia even in people without diabetes (Jadhav
2006), this eIect remains to be confirmed (Luo 2019). From a
clinical perspective, treatment with metformin has been linked to
a reduction in cardiovascular events in certain subpopulations,
including the obese and people with co-existing coronary heart
disease (UKPDS 1998; DPP Research Group 2012; Hong 2013;
Tanabe 2015).
Recently, DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2
inhibitors were approved for treating people with type 2 diabetes
mellitus (ADA 2018). Two large-scale randomised trials showed that
adding a SGLT-2 inhibitor to existing glucose-lowering medications
in people with type 2 diabetes mellitus and established CVD
led to a reduced risk of major adverse cardiovascular events
(MACE), defined as a composite of nonfatal myocardial infarction,
nonfatal stroke, and cardiovascular death (Zinman 2015; Neal
2017). Although the class eIect of SGLT-2 is currently unclear
(Wiviott 2019), a recent systematic review reported that treatment
with SGLT-2 inhibitors was eIective in minimising the rates of HF-
related hospitalisation, as well as renal disease progression, in
people with type 2 diabetes mellitus (Zelniker 2019).
Several studies have also shown that add-on treatment of GLP-1
receptor agonists (liraglutide and semaglutide) among people with
type 2 diabetes mellitus and CVD decreased their cardiovascular
risk compared with placebo (Marso 2016a; Marso 2016b). However,
it is worth noting that other GLP-1 receptor agonists (exenatide and
lixisenatide) showed no eIects against cardiovascular outcomes
(PfeIer 2015; Holman 2017); similarly, treatment with DPP-4
inhibitors did not lead to a reduction in cardiovascular risk (Scirica
2013; White 2013; Green 2015; Rosenstock 2019).
It is therefore clear that, despite increased global usage of DPP-4
inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors (Kim
2019), their precise eIects on reducing CV events in people with
high cardiovascular risks with or without diabetes mellitus are yet
to be fully evaluated.
How the intervention might work
Although metformin remains as the first-line pharmacotherapy to
manage hyperglycaemia in people with type 2 diabetes mellitus
with additional considerations of improved cardiac outcome (ADA
2019), evidence has recently emerged that DPP-4 inhibitors, GLP-1
receptor agonists and SGLT-2 inhibitors are viable pharmacological
treatment options for people with diabetes who are at risk
of CVD and in whom metformin monotherapy has failed or is
inadequate, giving demonstrable evidence of cardiovascular risk
reduction (Zinman 2015; Marso 2016a; Marso 2016b; Neal 2017).
In 2018, the American Diabetes Association's (ADA's) 'Standards of
Medical Care in Diabetes' introduced new recommendations for
the use of anti-diabetic drugs with proven cardiovascular benefit
in people with type 2 diabetes mellitus (ADA 2018). The guideline
states that, for people with type 2 diabetes and atherosclerotic
cardiovascular disease (ASCVD), therapy should start with lifestyle
management with metformin. The above-mentioned three drugs
(DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors)
will aIect cardiovascular outcome as an additional agent.
Considering their biological mechanisms of action, both DPP-4
inhibitors and GLP-1 receptor agonists are classified as 'GLP-1-
based therapies', referring to their actions on glycaemia control
through enhancement of glucose-dependent insulin secretion.
Glucose homeostasis is dependent upon a complex interplay of
multiple hormones. As one of the gastrointestinal peptides, GLP-1
is produced from the small intestine and secreted in response
to nutrients, stimulating insulin synthesis and insulin secretion
(Koliaki 2011). In people with type 2 diabetes mellitus, the insulin
response to GLP-1 becomes lower, possibly related to a reduction
in postprandial GLP-1 secretion (Vilsbøll 2001). Due to N-terminal
degradation by the DPP-4 enzyme, GLP-1 exhibits a short half-life.
GLP-1-based agents are therefore resistant to DPP-4 degradation
and are thus able to influence blood glucose control. SGLT-2
inhibitors are expressed in the proximal tubule, and mediate
reabsorption of approximately 90% of the filtered glucose load. The
Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people
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eIects of SGLT-2 inhibitors in people with diabetes are not only the
reduction of blood glucose levels but also lowering blood pressure
and body weight (Clar 2012).
As well as glucose-lowering eIects, several direct eIects of these
agents on cardiovascular systems have also been reported. In
people without diabetes mellitus, GLP-1-based therapies have
been shown to simultaneously exert an incretin eIect on insulin
secretion, illustrating a protective eIect on endothelial function
(Ceriello 2011). In addition, GLP-1-based agents could also reduce
arrhythmias and improve cardiac functions, such as leP ventricular
ejection fraction (LVEF) in heart failure (Sheikh 2013). The
mechanisms of these eIects remain to be fully explored, but
attenuated insulin resistance has been proposed as a possible
explanation (Ingelsson 2005).
Studies of SGLT-2 inhibitors have also demonstrated that blocking
endothelial sodium-glucose cotransporter-2 led to improved
endothelial function, which could be beneficial for non-diabetic
populations (Bairey Merz 2019; Pulakazhi 2019). A recent study
revealed that SLGT-2 inhibitors would be beneficial in people
with heart failure and without diabetes mellitus (McMurray
2019), the mechanisms of which could be explained by eIective
weight reduction. It is worth highlighting that the rationale
of using SGLT-2 inhibitors in people without diabetes mellitus
focuses on the observation that, while these agents were shown
to reduce cardiac events in people with diabetes mellitus,
the achieved glycaemic control was no better than what was
achieved with standard glucose-lowering agents. For example,
canagliflozin was found to slow the progression of renal disease
over two years in people with type 2 diabetes mellitus and the
illustrated renoprotection was independent from glycaemic control
(Heerspink 2017). The hypothesis that SGLT-2 inhibitors could be of
interest to populations with cardiovascular disease, namely heart
failure, prompted further clinical research. However, it is currently
unclear whether these novel antidiabetic agents truly reduce
cardiovascular events; comprehensive and methodologically-
sound systematic reviews assessing all these three drug classes are
lacking.
Why it is important to do this review
It is well recognised that CVD remains one of the most common
causes of death all over the world. Among many subtypes of
CVD, the rapidly-increasing number of people with HF, sometimes
referred to as the "heart failure pandemic", should be emphasised
(Ambrosy 2014; Shimokawa 2015). Given that diabetes mellitus
is a leading cause and an associated comorbidity of CVD,
eIective blood glycaemic control for people with or without CVD
became a global management target for both prevention and
treatment. Evidence for the beneficial eIects of the new glucose-
lowering agents (GLP-1 receptor agonists and SGLT-2 inhibitors) in
people with CVD appeared to be promising. Comprehensive and
systematic assessment of available study findings is warranted,
due to the rapidly-evolving evidence base. We are aware of several
published systematic reviews on this topic (Li 2016a; Li 2016b;
Savarese 2016; Wu 2016; Mannucci 2017; Zheng 2018), but this is the
first Cochrane Review to assess the cardiovascular eIects of these
novel agents in people with and without diabetes mellitus.
Among these three types of glucose-lowering interventions, SGLT-2
inhibitors has received considerable attention recently due to its
class eIect on CVD outcomes, even in non-diabetic populations.
As highlighted in a previous meta-analysis (Zelniker 2019), the
eIectiveness of SGLT-2 inhibitors varies by baseline patient
characteristics. SGLT-2 inhibitors reduced MACE (myocardial
infarction, stroke, or cardiovascular death), with benefits only seen
in people with ASCVD and not in the at-risk subgroup. In other
studies of DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2
inhibitors, people with CVD as well as people with cardiovascular
risk factors were considered as one study population group and
thus the true eIects of these novel agents in the two separate
subpopulations remain uncertain. A precise review of clinical
characteristics and the relative treatment eIects is therefore
needed, since a better understanding of appropriate target
populations for these new pharmacological agents is important for
optimal treatment pathways.
It is worth noting that these novel glucose-lowering agents are
provided either as an additional (add-on) treatment or as part of
triple combination therapy. Although these combinations might be
clinically valid and important, quantitative comparisons between
numerous groups of treatment modalities pose quite a challenge,
since head-to-head comparisons assessed by randomised pivotal
trials are not always available or feasible. We therefore plan to
conduct this Cochrane Review with a network meta-analysis to
investigate the eIectiveness of these agents with both direct and
indirect comparisons.
O B J E C T I V E S
To systematically review the available evidence on the eIects
(benefits and harms) of DPP-4 inhibitors, GLP-1 receptor agonists,
and SGLT-2 inhibitors in people with established CVD, using
network meta-analysis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs) at the individual
participant level as well as at cluster level. We will also include
cross-over trials by incorporating data from the first phase only,
i.e. before participants crossed over. We will include trials reported
as full-text, those published as abstract only, and unpublished
data. We will include trials irrespective of publication type, date, or
language. Given the nature of the moderate- to long-term outcome
measures (Types of outcome measures), we will only include trials
with a treatment duration of 24 weeks or longer.
Types of participants
We will consider all participants aged 18 years or older with the
following subtypes of CVD, with or without established type 2
diabetes mellitus.
• Atherosclerotic cardiovascular disease (ASCVD), i.e. people with
a history of acute coronary syndrome or myocardial infarction,
stable or unstable angina, coronary heart disease with or
without revascularisation, other arterial revascularisation,
stroke, or peripheral artery disease assumed to be
atherosclerotic in origin, as defined by the American College
of Cardiology (ACC) and American Diabetes Association (ADA)
guidelines).
Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people
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• Heart failure: heart failure with preserved ejection fraction
(HFpEF) or heart failure with reduced ejection fraction
(HFrEF), as defined by the European Society of Cardiology
(ESC) guidelines (Subgroup analysis and investigation of
heterogeneity).
For trials consisting of mixed populations (e.g. ASCVD and other
healthy population in primary prevention studies), we will extract
only data from desired participant subgroups. If the subgroup data
required are not provided, we will contact corresponding authors
of the trial to request this information. If the subgroup data are still
not available, we will exclude the whole trial if fewer than 80% of
participants fit the inclusion criteria. If the transitivity assumption
in the network meta-analysis is not plausible, we will implement
the 're-analysis' approach on the subset of the participants who
satisfy the above criteria.
Types of interventions
We will include RCTs comparing one or more of the following
interventions:
• DPP-4 inhibitors (DPP-4i);
• GLP-1 receptor agonists (GLP-1 RA);
• SGLT-2 inhibitors (SGLT-2i).
We will include trials using any combination of the above drugs.
We will not exclude trials on the basis of the route, dose,
timing, or frequency of drug administration. The comparison
groups will be as defined by the trial, which could be a
placebo, a lifestyle/behavioural intervention (e.g. diet, exercise,
diet + exercise), and another glucose-lowering pharmacological
intervention. We will combine trials which use a placebo, a
lifestyle/behavioural intervention, and another glucose-lowering
pharmacological intervention as a single comparator for the direct
comparison. Theoretically, the combination of DPP-4i and GLP-1
RA will not usually be recommended, but at this stage we do not
exclude the possibility.
Our comparisons are based on the aforementioned three types
of interventions, with each drug type corresponding to one node
in our network meta-analysis. We assume the concept of 'jointly
randomisable' could apply to all treatments included in the
network comprising these interventions and comparators.
Types of outcome measures
We will include outcome data reported at 30 days, one year, and the
longest follow-up duration.
Reporting one or more of the outcomes listed here is not a trial
inclusion criterion for the review. Where a published trial does not
report one of these outcomes, we will access the trial protocol
and contact the trial authors to ascertain whether the outcomes
were measured but not reported. Relevant trials which measured
these outcomes but did not report the data at all, or not in a




• Fatal or non-fatal myocardial infarction
• Fatal or non-fatal stroke
Secondary outcomes
• All-cause mortality
• Hospitalisation for heart failure
• Development of end-stage kidney disease
• Initiation of renal replacement therapy
• Non-cardiac safety outcomes, including hypoglycaemia, renal
toxicity, pancreatitis, fractures, and other adverse eIects as
reported by trial investigators
For the outcome of hospitalisation for heart failure, we will consider
the initial hospitalisation as an outcome. We will analyse safety
outcome data separately.
Search methods for identification of studies
Electronic searches
We will identify trials through systematic searches of the following
bibliographic databases:
• Cochrane Central Register of Controlled Trials (CENTRAL) in the
Cochrane Library;
• MEDLINE (Ovid, from 1946 onwards);
• Embase (Ovid, from 1980 onwards);
• Conference Proceedings Citation Index-Science (CPCI-S) (Web of
Science).
We will adapt the preliminary search strategy for MEDLINE (Ovid)
(Appendix 1) for use in the other databases. We will apply the
Cochrane sensitivity and precision-maximising RCT filter (Lefebvre
2019) to MEDLINE (Ovid) and adaptations of it to the other
databases, except for CENTRAL.
We will also conduct a search of ClinicalTrials.gov/ and the WHO
International Clinical Trials Registry Platform (ICTRP) Search Portal
(apps.who.int/trialsearch/) for ongoing or unpublished trials.
We will search all databases from their inception to the present, and
will impose no restriction by language of publication or publication
status.
We will not perform a separate search for adverse eIects, but will
consider any adverse eIects described in the included studies.
Searching other resources
We will check reference lists of all included trials and any relevant
systematic reviews identified for additional references to trials. We
will also examine any relevant retraction statements and errata for
included studies.
Data collection and analysis
Selection of studies
Two review authors (TK, AM) will independently screen titles and
abstracts for inclusion of all the potential studies we identify as a
result of the search, and will code them as 'retrieve' (eligible or
potentially eligible/unclear) or 'do not retrieve' (clearly irrelevant).
If there are any disagreements, we will ask a third review
author (JSWK) to arbitrate. We will retrieve the full-text study
reports/publication, and the two review authors (TK, AM) will
independently screen the full text and identify trials for inclusion,
recording reasons for exclusion of the ineligible studies. We will
Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people
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resolve any disagreement through discussion or, if required, we
will consult a third person (DY, JSWK). We will identify and exclude
duplicates and collate multiple reports of the same study, so that
each study rather than each report is the unit of interest in the
review. We will record the selection process in suIicient detail to
complete a PRISMA flow diagram and a 'Characteristics of excluded
studies' table (Liberati 2009).
Data extraction and management
We will use a data collection form for study characteristics
and outcome data which has been piloted on at least one
study in the review. One review author (TK) will extract study
characteristics from included studies. We will extract the following
study characteristics.
1. Methods: study design, total duration of study, details of any
'run-in' period, number of study centres and location, study
setting, and date of study.
2. Participants: N randomised, N lost to follow-up/withdrawn, N
analysed, mean age, age range, gender, weight, body mass index
(BMI), cardiovascular disease categories, severity of condition
(such as the commonly-used classification system, New York
Heart Association (NYHA) classification or the ACC/American
Heart Association (AHA) stages of heart failure), leP ventricular
ejection fraction, baseline diabetes condition including HbA1c,
smoking history, trial inclusion and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications, and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial, and notable conflicts of interest of trial
authors.
All included studies will use very similar inclusion criteria and
find comparable baseline characteristics. From each study, we will
extract the following characteristics that may have acted as eIect
modifiers: age, gender, BMI, and comorbidities.
Two review authors (TK, AM) will independently extract outcome
data from included studies. We will resolve disagreements by
consensus or by involving a third person (JSWK). One review author
(TK) will transfer data into the Review Manager 5 soPware file
(Review Manager 2014). We will double-check that data are entered
correctly by comparing the data presented in the review with the
data extraction form. A second review author (AM) will spot-check
study characteristics for accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors (TK, AM) will independently assess risks of bias
for each study, using the criteria outlined in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2019a). We will
resolve any disagreements by discussion or by involving another
review author (JSWK). We will assess the risks of bias according to
the following domains.
• Random sequence generation;
• Allocation concealment;
• Blinding of participants and personnel;
• Blinding of outcome assessment;
• Incomplete outcome data;
• Selective outcome reporting;
• Other potential bias.
We will grade each potential source of bias as high, low or unclear,
and will provide a quote from the trial report together with a
justification for our judgement in the 'Risk of bias' table. We will
summarise the 'Risk of bias' judgements across diIerent trials for
each of the domains listed. Where information on risk of bias relates
to unpublished data or correspondence with the trialists, we will
note this in the 'Risk of bias' table.
When considering treatment eIects, we will take into account the
risk of bias for the trials that contribute to that outcome. We plan to
use the Confidence in Network Meta-Analysis (CINeMA) approach to
calculate and visualise the percentage contribution of each direct
contrast to each network estimate (Nikolakopoulou 2020).
Assessment of bias in conducting the systematic review
We will conduct the review according to this published protocol,
and will report any deviations from it in the 'DiIerences between
protocol and review' section of the full review.
Measures of treatment e<ect
We will analyse all our outcome measures, which are all
dichotomous outcomes, using risk ratios (RRs) with 95% confidence
intervals (CIs). For eIicacy, an RR greater than 1.0 favours the
intervention (as opposed to the comparator); when we address
safety outcomes, an RR greater than 1.0 favours the comparator.
Unit of analysis issues
All of our included trials will be RCTs at the individual participant
or at the cluster level. Our types of interventions of interest are less
likely to be evaluated in a cluster-randomisation setting; however,
if there is more than one eligible cluster-randomised trial, we
will reduce participant numbers in cluster-randomised trials to
an eIective sample size by a sample size reduction calculation
(Hauck 1991). We will analyse data from cluster-randomised trials
with those from individually-randomised trials. If adjustment for
the cluster design eIect is missing from the trial reports, we will
adjust the relevant summary statistics (such as sample sizes and
standard deviations) according to the methods described in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2019b), using an estimate of the intraclass correlation coeIicient
(ICC) derived from the trial where possible, or from a similar trial,
or from a study of a similar population. If we use ICCs from other
sources in updates, we will perform sensitivity analyses to test the
eIects of variation in the ICC.
For trials that measured outcomes at diIerent time points, we
are interested only in eIects of the interventions from the longest
follow-up duration. Network meta-analysis is particularly helpful
in taking account of the comparison of multiple interventions.
If we identify multi-arm trials, to perform direct pairwise
comparisons we will treat these multiple treatment comparisons
as individual, independent two-arm trials. Network meta-analysis
gives consideration to a correlation between eIect sizes from trials
with more than two arms, and we will take into account the
respective treatment eIects from the same studies.
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Dealing with missing data
We will contact the investigators/authors of the included trials
to request any missing data. Our default approach will be to
analyse data by following intention-to-treat principles. To explore
the impact of missing data, we will conduct sensitivity analysis
by including trials that reported data using an intention-to-treat
approach, and compare the results with those from the overall
analysis that includes trials following either an intention-to-treat or
a per-protocol approach (Sensitivity analysis).
Assessment of heterogeneity
We will inspect forest plots to identify signs of heterogeneity for
each direct comparison. We will assess the presence of statistical
heterogeneity and quantify it using the Chi2 test (threshold P
< 0.10), and the I2 statistic, respectively. The importance of the
observed value of I2 depends on both the magnitude and the
direction of eIects and strength of evidence for heterogeneity.
Uncertainty in the value of I2 is substantial when the number of
trials is small. We will follow the recommendations for thresholds
in the Cochrane Handbook for Systematic Reviews of Interventions
(Deeks 2019):
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
If we identify important heterogeneity we will report it and explore
possible causes by prespecified subgroup analysis and meta-
regression (Subgroup analysis and investigation of heterogeneity).
If we find considerable heterogeneity, we will not pool the results
but will describe them narratively.
Assessment of reporting biases
If we are able to pool more than 10 trials, we will create and examine
a funnel plot to visually explore possible small-study biases for the




We will conduct direct pairwise meta-analysis using Review
Manager 2014. If there are two or more included studies for
an outcome measure, we will consider pooling the results
depending on the level of statistical heterogeneity among the
trials (Assessment of heterogeneity). We will use both fixed-
eIect and random-eIects analytical models for direct comparison
meta-analysis if we classify the heterogeneity as moderate. If
the heterogeneity is considerable, we will not pool the results
but instead will perform a narrative synthesis. We will also
perform subgroup analyses if we detect any source of important
heterogeneity between studies as assessed and quantified by the
Chi2 test and the I2 statistics (Subgroup analysis and investigation
of heterogeneity).
Network meta-analysis
For indirect and mixed comparisons, we will use network meta-
analysis to obtain estimates for the outcomes, and present these
estimates as risk ratios (RRs) with 95% confidence intervals (CIs).
We will conduct our network meta-analysis for all outcome data
measured at the following time points: 30 days, one year, and
longest follow-up visit. We will perform network meta-analyses
within a frequentist framework, assuming an equal heterogeneity
parameter across all comparisons, and will then create network
diagrams to visually check the direct or indirect comparisons. To
estimate the relative ranking probability of an intervention being
among the best options, we will calculate for all outcomes the
surface under the cumulative ranking (SUCRA) curve, and mean
ranks (Salanti 2011). Larger SUCRA scores mean a more eIective
or safer intervention. To check for the presence of inconsistency
in the estimated diagram, we will use the loop-specific approach
to analyse the statistical diIerence between direct and indirect
estimates for a certain comparison in a loop. The measure of
inconsistency will be based on the Bucher method, as described
in Dias 2013 and Schwarzer 2015, who recommend the use of
generalised Cochrane's Q and I2 test statistics. We will also use
a net-heat plot to highlight inconsistency in the network. The
net-heat plot is a matrix imaging that emphasises hotspots of
inconsistency in the network and renders possible drivers. If
quantitative synthesis is not possible, we will give a narrative
review of the findings.
We will perform the analysis using R, version 3.4.2 (R 2017), netmeta
package (netmeta); the codes and description of the methodology
can be found in netmeta itself.
Subgroup analysis and investigation of heterogeneity
We will investigate possible heterogeneity through subgroup
analyses in both the direct and the network meta-analyses. This will
be based on the presence of statistical heterogeneity considered
to be important (I2 > 40%, as calculated by Review Manager
2014) in the standard direct-comparison meta-analysis, together
with underlying clinical heterogeneity in baseline participant
characteristics.
We will consider the following subgroups.
• Type of baseline CVD:
* participants with clinically-diagnosed ASCVD (further
stratified by the type of ASCVD, e.g. acute coronary
syndrome, coronary heart disease with or without
revascularisation);
* participants with clinically-confirmed heart failure (further
stratified by leP ventricular ejection fraction (LVEF) status,
where normal LVEF (heart failure with preserved EF, HFpEF)
is typically considered as EF of ≥ 50% and reduced LVEF
(heart failure with reduced EF, HFrEF) is defined as EF < 40%)
(Ponikowski 2016).
• Background comorbidities (diabetes mellitus, chronic kidney
disease (CKD)).
• Type of active treatment (individual DPP-4 inhibitors/GLP-1
receptor agonists/SGLT-2 inhibitors).
• Type of control (placebo, lifestyle intervention, another glucose-
lowering pharmacological intervention).
• Duration of study (≤ 52 weeks vs. > 52 weeks).
• Mode of therapy (monotherapy or combination therapy).
Our outcome measures for the above subgroup analyses are:
• cardiovascular mortality;
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• fatal or non-fatal myocardial infarction;
• fatal or non-fatal stroke;
• all-cause mortality.
We will use the formal test for subgroup diIerences in Review
Manager 2014, and base our interpretation on this.
Sensitivity analysis
We plan to carry out sensitivity analysis to test whether key
methodological factors or decisions may have aIected the main
results of our direct-comparison meta-analysis.
We will perform the following sensitivity analyses by only including:
• trials assessed at low risk of bias (i.e. for which we rate all
domains at low risk);
• trials adopting an intention-to-treat approach for data analysis;
• trials published as full-text articles.
Our outcome measures for these sensitivity analyses are:
• cardiovascular mortality;
• fatal or non-fatal myocardial infarction;
• fatal or non-fatal stroke;
• all-cause mortality;
Reaching conclusions
We will base our conclusions only on findings from the quantitative
or narrative synthesis of included studies for this review. We will
avoid making recommendations for practice, and our implications
for research will suggest priorities for future research, and will
outline what the remaining uncertainties are in the area.
Summary of findings and assessment of the certainty of the
evidence
We will create a 'Summary of findings' table using the following
primary and secondary outcomes (Types of outcome measures):
1. cardiovascular mortality;
2. fatal or non-fatal myocardial infarction;
3. fatal or non-fatal stroke;
4. all-cause mortality;
5. hospitalisation for heart failure;
6. non-cardiac safety outcomes including hypoglycaemia, renal
toxicity, pancreatitis, fractures, and other adverse eIects as
reported by study investigators.
We will use the five Grading of Recommendations Assessment,
Development and Evaluation (GRADE) considerations (study
limitations, consistency of eIect, imprecision, indirectness and
publication bias) to assess the quality of a body of evidence
as it relates to the studies which contribute data to the meta-
analyses for the prespecified outcomes. We will use methods
and recommendations described in the Cochrane Handbook for
Systematic Reviews of Interventions (Schünemann 2019), using the
GRADEpro soPware (GRADEpro GDT 2015).
We will produce a 'Summary of findings' table for the following
comparisons (Types of interventions).
• active monotherapy treatment group versus a combined control
group (placebo or lifestyle/behavioral interventions or another
active treatment)
• active combination therapy group versus a combined control
group;
We will justify all decisions to downgrade the quality of studies
using footnotes and we will make comments to aid reader's
understanding of the review where necessary.
Judgements about evidence quality will be made by two review
authors (TK and AM) working independently, with disagreements
resolved by discussion or involving a third author (JSWK).
Judgements will be justified, documented and incorporated into
reporting of results for each outcome. For rating of evidence across
studies in a network meta-analysis, we will follow the approach
recently released by the GRADE Working Group (Puhan 2014).
We plan to extract study data, format our comparisons in data
tables and prepare a 'Summary of findings' table before writing
the results and conclusions of our review. A template is included
as Table 1, which refers to a 'Summary of findings' table for direct
comparison. We will also include a separate table to illustrate
results from our network meta-analysis as per the recent guidance
from Yepes-Nuñez 2019.
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Patient or population: Adults with clinically diagnosed CVD
Setting: Hospital
Intervention: DPP4-inhibitors or GLP-1 receptor agonists or SGLT-2 inhibitors (monotherapy or combination therapy)





















Table 1.   Template of 'Summary of findings' table (direct comparison) 
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*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI).
Table 1.   Template of 'Summary of findings' table (direct comparison)  (Continued)
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CI: Confidence interval; RR: Risk ratio; OR: Odds ratio.
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the
effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the
estimate of effect
Table 1.   Template of 'Summary of findings' table (direct comparison)  (Continued)
 
 
A P P E N D I C E S
Appendix 1. Preliminary MEDLINE (Ovid) search strategy
1 exp Dipeptidyl-Peptidase IV Inhibitors/ (4613)
2 (Dipeptidyl peptidase 4 adj2 inhibitor*).tw. (2193)
3 (Dipeptidyl peptidase IV adj2 inhibitor*).tw. (642)

















21 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 (7420)
22 Glucagon-like peptide-1 receptor agonist*.tw. (1480)
23 GLP-1 receptor agonist*.tw. (1663)
24 incretin mimetic*.tw. (335)
Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people
with cardiovascular disease: a network meta-analysis (Protocol)



















34 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 (6987)
35 exp Sodium-Glucose Transporter 2 Inhibitors/ (2077)
36 sodium-glucose cotransporter-2 inhibitor*.tw. (891)







44 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 (3960)
45 21 or 34 or 44 (16166)
46 Cardiovascular Diseases/ (144221)
47 Cardiovascular disease*.tw. (162179)
48 (CVD or ASCVD).tw. (34799)
49 coronary disease/ or coronary artery disease/ (187621)
50 (Coronary adj2 disease*).tw. (141468)
51 CAD.tw. (37441)
52 Acute Coronary Syndrome/ (14963)
53 acute coronary syndrome.tw. (20545)
54 ACS.tw. (20938)
55 exp Myocardial Infarction/ (172644)
56 myocardial infarction*.tw. (177201)
57 heart attack*.tw. (5381)
58 exp Angina Pectoris/ (43141)
59 angina.tw. (51817)
Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people
with cardiovascular disease: a network meta-analysis (Protocol)
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60 exp Heart Diseases/ (1108135)
61 heart disease*.tw. (161229)
62 (CHD or IHD).tw. (29532)
63 revasculari?ation.tw. (55225)
64 exp Coronary Artery Bypass/ (52210)
65 coronary artery bypass.tw. (39637)
66 CABG.tw. (17425)
67 exp Percutaneous Coronary Intervention/ (52160)
68 (Percutaneous adj2 coronary).tw. (40001)
69 PCI.tw. (24438)




74 Peripheral Arterial Disease/ (7200)
75 peripheral arter* disease*.tw. (13152)
76 Heart Failure/ (115420)
77 ((heart or cardiac) adj2 failure).tw. (171042)
78 (HF or CHF or CCF).tw. (57803)
79 HFpEF.tw. (2129)
80 HFrEF.tw. (1591)
81 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or
70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 (1749014)
82 45 and 81 (2681)
83 randomized controlled trial.pt. (500168)
84 controlled clinical trial.pt. (93531)
85 randomized.ab. (469108)
86 placebo.ab. (204791)
87 clinical trials as topic.sh. (190121)
88 randomly.ab. (326911)
89 trial.ti. (212770)
90 83 or 84 or 85 or 86 or 87 or 88 or 89 (1267648)
91 exp animals/ not humans.sh. (4670680)
92 90 not 91 (1165893)
93 82 and 92 (939)
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